Skip to content

Why partner with us

Prioritized list icon

Get a prioritized list of your evaluated precision repositioning opportunities matched to patient subgroups

Full data packages icon

Full data packages supporting method of use patent filing for assets in new indications

License patient stratification biomarkers icon

Patient stratification biomarkers identifying potential responders for the secondary indication

Ongoing evaluation icon

Ongoing evaluation of secondary indication potential for your pipeline and in-licensing assets

Partnering with us

Maximize portfolio returns

We evaluate marketed drugs, current development candidates, and in-licensed assets to identify and validate precision repositioning opportunities, prioritizing those with the highest market potential and quickest route to market.

Our evaluation includes detailed analyses of each asset’s:

  • Disease prevalence & patient stratification
  • Mechanism of action hypothesis
  • Efficacy potential
  • Dosage and route of administration
  • Safety & toxicity
  • Published & proprietary clinical evidence
  • FTO & composition of matter patent life
  • Regulatory environment
  • Revenue potential
View our pipeline
8.PARKINSONS-min
License assets with high value and efficacy potential-min

License assets with high value and efficacy potential

Understanding the near-term repositioning opportunities creates additional revenue opportunities by putting drugs on the market quicker and cheaper in secondary indications and by providing complementary diagnostics tools alongside each out-licensing drug program.

Match treatments to patients in trials and the clinic

Our companion stratification biomarkers accurately match your targets to the subgroups of patients who are likely to show positive treatment response from drugs targeting those mechanisms in new indications - accelerating market approval and increasing value-based returns.

Match treatments to patients in trials and the clinic-min
Stay ahead of your competition-min

Stay ahead of your competition

Our coverage of chronic diseases is growing rapidly. We're adding two new indications to DiseaseBank every month. With INDx you will be notified of opportunities to license assets in these new indications.

As an INDx subscriber, you'll never miss an opportunity to:

  • Evaluate your latest target pipeline against a continually growing set of indications
  • Identify secondary indications for your program acquisition options and in-licensing prospects
  • Influence the order of new disease indications for inclusion in DiseaseBank

Benefits of our unique approach

We’ve uncovered the mechanistic architecture and biological drivers of diseases at an unprecedented level of detail across dozens of major disorders.

These proprietary insights are stored in DiseaseBank™ ready to systematically map your assets to clinically relevant patient subgroups who will benefit from drugs targeting those mechanisms in secondary indications.

Learn more about our Innovation Engine

Maximize your portfolio returns

Repurpose your drugs and candidates as valuable new precision medicines, at reduced risk and cost, maximizing the returns on your R&D

Contact us